ATE411387T1 - Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren - Google Patents

Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren

Info

Publication number
ATE411387T1
ATE411387T1 AT01933020T AT01933020T ATE411387T1 AT E411387 T1 ATE411387 T1 AT E411387T1 AT 01933020 T AT01933020 T AT 01933020T AT 01933020 T AT01933020 T AT 01933020T AT E411387 T1 ATE411387 T1 AT E411387T1
Authority
AT
Austria
Prior art keywords
rabies virus
human monoclonal
nucleic acid
monoclonal antibodies
related methods
Prior art date
Application number
AT01933020T
Other languages
German (de)
English (en)
Inventor
Douglas Hooper
Bernhard Dietzschold
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Application granted granted Critical
Publication of ATE411387T1 publication Critical patent/ATE411387T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01933020T 2000-05-16 2001-05-04 Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren ATE411387T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20451800P 2000-05-16 2000-05-16

Publications (1)

Publication Number Publication Date
ATE411387T1 true ATE411387T1 (de) 2008-10-15

Family

ID=22758233

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01933020T ATE411387T1 (de) 2000-05-16 2001-05-04 Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren

Country Status (9)

Country Link
US (1) US6890532B2 (https=)
EP (1) EP1282703B1 (https=)
JP (1) JP4819285B2 (https=)
AT (1) ATE411387T1 (https=)
CA (1) CA2419148C (https=)
DE (1) DE60136174D1 (https=)
IL (1) IL152825A (https=)
RU (1) RU2272809C2 (https=)
WO (1) WO2001088132A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
AU2001281151A1 (en) * 2000-08-24 2002-03-04 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
NZ531291A (en) * 2001-08-21 2006-02-24 Univ Jefferson Recombinant anti rabies antibodies MAb JB.1 and Mab 57 and compositions and methods for making and using the same
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
ME01785B (me) * 2005-02-02 2014-09-20 Univ Massachusetts Humana antitijela protiv bjesnila i njihove upotrebe
JP2008263964A (ja) * 2007-03-29 2008-11-06 Yamaguchi Univ コウモリ由来細胞株
JP2010085126A (ja) * 2008-09-29 2010-04-15 Adtec Kk 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法
CN103492419B (zh) * 2011-03-18 2015-11-25 赛特瑞恩股份有限公司 可中和狂犬病病毒的结合分子
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
RU2533802C1 (ru) * 2013-08-30 2014-11-20 федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Тримеризованное однодоменное антитело, специфически связывающееся с гликопротеином g вируса бешенства, нейтрализующее вирус бешенства
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
CN111166877A (zh) * 2019-12-30 2020-05-19 西安回天血液制品有限责任公司 一种狂犬病人免疫球蛋白的制备方法
CN114958774B (zh) * 2022-05-08 2023-10-27 中国医学科学院医学生物学研究所 抗狂犬病病毒单克隆抗体及分泌该抗体的杂交瘤细胞株与应用
CN119431525B (zh) * 2024-10-08 2025-04-11 北京溯本源和生物科技有限公司 狂犬病毒g蛋白重组抗原、单克隆抗体及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
JPH02503751A (ja) * 1988-04-07 1990-11-08 フアルミタリア・カルロ・エルバ・エツセ・エルレ・エルレ 狂犬病ウイルス細胞を特異的に認識するヒトモノクローナル抗体、それを産生する細胞、それを含有する処方物及びそれら全ての製造方法
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES

Also Published As

Publication number Publication date
US6890532B2 (en) 2005-05-10
JP2004528803A (ja) 2004-09-24
CA2419148C (en) 2011-07-12
IL152825A0 (en) 2003-06-24
DE60136174D1 (de) 2008-11-27
EP1282703A2 (en) 2003-02-12
RU2272809C2 (ru) 2006-03-27
EP1282703B1 (en) 2008-10-15
CA2419148A1 (en) 2001-11-22
WO2001088132A2 (en) 2001-11-22
WO2001088132A3 (en) 2002-07-18
IL152825A (en) 2009-07-20
JP4819285B2 (ja) 2011-11-24
US20030165507A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
ATE411387T1 (de) Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
DK1578936T3 (da) Humane anti-IFN-gamma-neutraliserende antistoffer som selektive inhibitorer af IFN-gamma-vejen
DK1355930T3 (da) Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
TR200300478T2 (tr) Hümanize antiLT-ß-R antikorları
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
NZ619953A (en) Human cytomegalovirus neutralizing antibodies and use thereof
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
NZ590891A (en) Neutralizing anti-influenza a virus antibodies and uses thereof
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
BR0316758A (pt) Vacinas baseadas em levedura como imunoterapia
ATE288502T1 (de) Gezieltes antikörper-verfahren
HRP20030089B1 (hr) Anti-tnf protutijela, pripravci, postupci i primjena
CY1113037T1 (el) Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
NO970221D0 (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
WO2003039470A3 (en) Polyvalent immunogen of hiv
EP1530579A4 (en) RECOMBINANT ANTIBODIES AND COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE THEREOF
DE60231475D1 (de) Materialien und methoden zur behandlung von hepatitis c
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
ATE99958T1 (de) Monoklonale antikoerper zur behandlung nach einem kontakt mit tollwutvirus.
CY1105549T1 (el) Καινουργια μεθοδος θεραπειας
EA200200927A1 (ru) Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
DE602006016416D1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties